Breaking Studies - Masimo's Technologies the Focus of Multiple Clinical Studies at Last Week's American Society of Anesthesiologists' Annu...( New studies show Masimo provides ...),Health

New studies show Masimo provides unique benefits in pulse oximetry, as well as

noninvasive blood constituent and functional hemodynamic monitoring

IRVINE, Calif., Oct. 25 /PRNewswire-FirstCall/ Masimo, the inventor of Pulse CO-Oximetry and Read-Through Motion and Low Perfusion pulse oximetry, reported that multiple independent and objective clinical studies and a case study were presented last week at the 2007 American Society of Anesthesiology (ASA) Annual Meeting in San Francisco focused on the unique benefits of Masimo's noninvasive patient monitoring technologies in helping clinicians provide improved patient care. These new studies add to the more than 100 independent and objective studies demonstrating the superiority of Masimo SET pulse oximetry, as well as adding to the growing body of research proving the efficacy of Masimo Rainbow SET in providing accurate, reliable physiological measurements of multiple blood constituents that previously required invasive procedures.

Built on the "gold-standard" of Masimo SET Read-Through Motion and Low Perfusion technology, Masimo Rainbow SET is the first and only upgradeable technology platform capable of continuously and noninvasively measuring carboxyhemoglobin (SpCO), methemoglobin (SpMet) and pleth variability index (PVI), in addition to oxyhemoglobin (SpO2), perfusion index (PI) and pulse rate. Highlights of key study findings include:

Masimo SET and Blue Sensor more accurate and more reliable in cyanotic children

In a study entitled "New Generation and Old Generation Pulse Oximeters in Children with Cyanotic Congenital Heart Disease" a team of anesthesiologists headed by Dr. Maxime Cannesson at the Louis Pradel Hospital in Lyon, France, found that in a study of 10 children ages seven days to 53 months following palliative cardiac surgery, Masimo obtained readings 100% of the time and "Nellcor failed to obtain readings 15% of the time." Additionally, findings showed a "significa
'/>"/>